IL6 and inflammatory bowel disease: Furthermore, anti-IL-6 therapy in IBD patients ameliorated the disease, but increased the risk of developing GI abscesses and perforation (99), suggesting that IL-6 contribute to inflammatory processes, but also may maintain epithelial barrier.